WST West Pharmaceutical Services, Inc.
Stock · NYSE · United States · Healthcare · US9553061055
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by West Pharmaceutical Services, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:38. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 18 Feb 2027 08:00 | 2.28 | — | — | Upcoming |
| 29 Oct 2026 06:00 | 2.20 | 2.66 | +21.1% | Beat |
| 23 Jul 2026 06:00 | 2.08 | 2.37 | +13.9% | Beat |
| 23 Apr 2026 06:00 | 1.68 | 2.13 | +27.1% | Beat |
| 12 Feb 2026 06:00 | 1.83 | 2.04 | +11.5% | Beat |
| 23 Oct 2025 06:00 | 1.71 | 1.96 | +14.6% | Beat |
| 24 Jul 2025 06:00 | 1.54 | 1.84 | +19.7% | Beat |
| 24 Apr 2025 06:00 | 1.26 | 1.45 | +15.3% | Beat |
| 13 Feb 2025 06:00 | 1.73 | 1.82 | +5.3% | Beat |
| 24 Oct 2024 06:00 | 1.49 | 1.85 | +23.8% | Beat |
| 25 Jul 2024 06:00 | 1.73 | 1.52 | -12.1% | Miss |
| 25 Apr 2024 06:00 | 1.29 | 1.56 | +21.2% | Beat |
| 15 Feb 2024 06:00 | 1.78 | 1.83 | +2.7% | Beat |
| 26 Oct 2023 06:00 | 1.86 | 2.16 | +16.2% | Beat |
| 27 Jul 2023 06:00 | 1.93 | 2.11 | +9.5% | Beat |
| 27 Apr 2023 06:00 | 1.67 | 1.98 | +18.8% | Beat |
| 16 Feb 2023 06:00 | 1.38 | 1.77 | +28.6% | Beat |
| 27 Oct 2022 06:00 | 2.12 | 2.03 | -4.3% | Miss |
| 28 Jul 2022 06:00 | 2.21 | 2.47 | +11.9% | Beat |
| 28 Apr 2022 06:00 | 2.12 | 2.30 | +8.5% | Beat |
| 17 Feb 2022 06:00 | 1.92 | 2.04 | +6.5% | Beat |
| 28 Oct 2021 06:00 | 1.80 | 2.06 | +14.6% | Beat |
| 29 Jul 2021 06:00 | 1.74 | 2.46 | +41.4% | Beat |
| 29 Apr 2021 06:00 | 1.43 | 2.05 | +43.6% | Beat |
| 18 Feb 2021 06:00 | 1.13 | 1.34 | +19.1% | Beat |
| 22 Oct 2020 06:00 | 0.99 | 1.15 | +15.7% | Beat |
| 23 Jul 2020 06:00 | 0.92 | 1.25 | +35.4% | Beat |
| 23 Apr 2020 06:00 | 0.82 | 1.01 | +22.9% | Beat |
| 13 Feb 2020 06:00 | 0.72 | 0.82 | +13.6% | Beat |
| 24 Oct 2019 06:00 | 0.71 | 0.79 | +11.6% | Beat |
| 25 Jul 2019 06:00 | 0.72 | 0.89 | +23.3% | Beat |
| 25 Apr 2019 06:00 | 0.66 | 0.74 | +12.7% | Beat |
| 14 Feb 2019 06:00 | 0.72 | 0.73 | +1.4% | Beat |
| 25 Oct 2018 06:00 | 0.70 | 0.76 | +8.6% | Beat |
| 26 Jul 2018 06:00 | 0.67 | 0.70 | +4.0% | Beat |
| 26 Apr 2018 06:00 | 0.64 | 0.62 | -2.7% | Miss |
| 15 Feb 2018 06:00 | 0.63 | 0.64 | +1.6% | Beat |
| 26 Oct 2017 07:00 | 0.53 | 0.67 | +26.8% | Beat |
| 27 Jul 2017 06:00 | 0.65 | 0.66 | +2.2% | Beat |
| 27 Apr 2017 07:00 | 0.56 | 0.60 | +8.1% | Beat |
| 16 Feb 2017 07:00 | 0.56 | 0.54 | -2.7% | Miss |
| 27 Oct 2016 07:00 | 0.53 | 0.53 | +1.0% | In line |
| 28 Jul 2016 07:00 | 0.56 | 0.59 | +4.6% | Beat |
| 28 Apr 2016 07:00 | 0.51 | 0.53 | +5.0% | Beat |
| 18 Feb 2016 07:00 | 0.47 | 0.47 | 0.0% | In line |
| 29 Oct 2015 07:00 | 0.43 | 0.44 | +2.9% | Beat |
| 30 Jul 2015 07:00 | 0.45 | 0.47 | +5.0% | Beat |
| 30 Apr 2015 07:00 | 0.40 | 0.45 | +13.4% | Beat |
| 19 Feb 2015 07:00 | 0.46 | 0.45 | -2.7% | Miss |
| 30 Oct 2014 07:00 | 0.44 | 0.44 | 0.0% | In line |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 3.1B | +6.3% | 493.7M | 16.1% | 6.79 | +1.5% | 468.9M |
| 2024 | 2.9B | -1.9% | 492.7M | 17.0% | 6.69 | -15.1% | 276.4M |
| 2023 | 2.9B | +2.2% | 593.4M | 20.1% | 7.88 | +1.9% | 414.5M |
| 2022 | 2.9B | — | 585.9M | 20.3% | 7.73 | — | 439.4M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 06 Nov 2026 | 389.62 | 402.40 | 386.88 | 399.81 | +1.87% | 625,900 | |
| 05 Nov 2026 | 408.54 | 409.81 | 392.12 | 392.48 | -3.99% | 872,800 | |
| 04 Nov 2026 | 416.46 | 416.46 | 405.12 | 408.78 | +0.44% | 1,054,900 | |
| 03 Nov 2026 | 407.39 | 416.23 | 404.52 | 406.99 | -0.22% | 1,075,800 | |
| 02 Nov 2026 | 412.89 | 418.50 | 407.14 | 407.88 | -1.15% | 1,456,600 | |
| 30 Oct 2026 | 419.06 | 422.08 | 407.67 | 412.62 | -0.97% | 1,062,300 | |
| 29 Oct 2026 | 420.69 | 438.27 | 415.32 | 416.67 | +3.23% | 1,872,800 | |
| 28 Oct 2026 | 396.95 | 404.99 | 396.83 | 403.64 | +1.34% | 773,200 | |
| 27 Oct 2026 | 392.90 | 398.67 | 391.78 | 398.29 | +0.90% | 790,700 | |
| 26 Oct 2026 | 389.80 | 395.28 | 388.06 | 394.73 | +0.66% | 649,600 | |
| 23 Oct 2026 | 391.60 | 394.18 | 389.72 | 392.15 | -0.48% | 718,000 | |
| 22 Oct 2026 | 394.15 | 397.16 | 389.17 | 394.03 | +0.14% | 679,900 | |
| 21 Oct 2026 | 381.98 | 396.00 | 381.98 | 393.48 | +1.21% | 573,700 | |
| 20 Oct 2026 | 387.54 | 389.75 | 384.21 | 388.78 | +1.27% | 569,700 | |
| 19 Oct 2026 | 383.78 | 387.01 | 383.20 | 383.91 | -0.03% | 312,800 | |
| 16 Oct 2026 | 382.74 | 386.26 | 380.28 | 384.02 | +0.26% | 511,200 | |
| 15 Oct 2026 | 377.00 | 384.40 | 376.10 | 383.02 | +2.23% | 390,400 | |
| 14 Oct 2026 | 372.21 | 379.21 | 372.21 | 374.65 | +0.76% | 444,600 | |
| 13 Oct 2026 | 369.54 | 378.84 | 367.50 | 371.82 | +1.15% | 507,600 | |
| 12 Oct 2026 | 366.72 | 371.76 | 363.10 | 367.60 | +0.44% | 357,300 | |
| 09 Oct 2026 | 363.31 | 370.20 | 362.18 | 366.00 | +0.75% | 480,200 | |
| 08 Oct 2026 | 365.65 | 367.25 | 359.49 | 363.27 | -0.88% | 461,700 | |
| 07 Oct 2026 | 371.66 | 374.79 | 365.35 | 366.48 | -1.65% | 438,000 | |
| 06 Oct 2026 | 379.02 | 381.16 | 367.64 | 372.64 | -1.09% | 401,400 | |
| 05 Oct 2026 | 364.69 | 377.06 | 363.16 | 376.76 | +3.23% | 682,700 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- West Pharmaceutical Services (WST) is a Great Momentum Stock: Should You Buy? (opens in a new tab) Zacks · 05 Nov 2026 16:00
- West Pharmaceutical Services Consensus Price Target Raised 12.52% to $467.89 (opens in a new tab) Fintel · 02 Nov 2026 12:58
- How Investors Are Reacting To West (WST) Earnings Beat (opens in a new tab) Simply Wall St. · 01 Nov 2026 19:08
- West Pharmaceutical Services (WST) Lifted Its Outlook, Is The Stock Fully Priced? (opens in a new tab) Simply Wall St. · 01 Nov 2026 18:07
- WST Q3 deep dive: Biologics and regulatory tailwinds fuel margin expansion, HVP mix shift continues (opens in a new tab) StockStory · 01 Nov 2026 02:03
- What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 31 Oct 2026 06:14
- West Pharmaceutical Services, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 29 Oct 2026 21:27
- West (WST) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 29 Oct 2026 17:14
- West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised (opens in a new tab) Zacks · 29 Oct 2026 15:04
- Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics (opens in a new tab) Zacks · 29 Oct 2026 12:30
- West Pharmaceutical Services (NYSE:WST) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations (opens in a new tab) StockStory · 29 Oct 2026 10:17
- West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates (opens in a new tab) Zacks · 29 Oct 2026 10:10
- West Pharmaceutical: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 29 Oct 2026 10:04
- West (WST) Stock Could Be 28% Overvalued As Cash Flow Falls Short (opens in a new tab) Simply Wall St. · 29 Oct 2026 01:11
- West Pharmaceutical (WST) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (opens in a new tab) Zacks · 28 Oct 2026 12:15
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 392.48 USD
- Market cap
- 27.9B
- Dividend yield
- 0.26%
- 5-year average yield
- 0.25%
- Payout ratio
- 10%
- Last dividend
- 0.2200 USD · 10 Nov 2026
- Next ex-dividend date
- 10 Nov 2026
- Exchange
- NYSE
- Country
- United States
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 29 Jul 2026 | 0.2200 USD |
| 29 Apr 2026 | 0.2200 USD |
| 28 Jan 2026 | 0.2200 USD |
| 12 Nov 2025 | 0.2200 USD |
| 30 Jul 2025 | 0.2100 USD |
| 30 Apr 2025 | 0.2100 USD |
| 07 Feb 2025 | 0.2100 USD |
| 13 Nov 2024 | 0.2100 USD |
| 31 Jul 2024 | 0.2000 USD |
| 23 Apr 2024 | 0.2000 USD |
| 30 Jan 2024 | 0.2000 USD |
| 07 Nov 2023 | 0.2000 USD |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble. | 1.1 / 25 |
|
| Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover. | 25.0 / 25 |
|
| Dividend growth How many years in a row the dividend has risen, and how fast. | 13.8 / 15 |
|
| Quality Return on equity, net margin and how stable the margins are. | 14.1 / 15 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 1.8 / 10 |
|
| Analysts How far the analysts' average target is from today's price. | 4.6 / 5 |
|
Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 44.87× | Weak | 30.65× |
| P/E (forward) | 38.47× | Weak | 14.89× |
| Price / book | 9.4× | Weak | 3.81× |
| Price / sales | 8.2× | Weak | 3.19× |
| EV / EBITDA | 28.82× | Weak | 12.63× |
| Free cash flow yield | 1.2% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 37.6% | Fair | 58.6% |
| Operating margin | 25.4% | Good | 7.8% |
| Net margin | 18.8% | Good | 2.8% |
| Return on equity | 21.2% | Good | 5.7% |
| Return on assets | 11.9% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 2.1% | Weak | 10.8% |
| EPS growth / year | -4.2% | Weak | 9.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.11× | Good | 0.48× |
| Net debt / EBITDA | -0.16× | Good | 1.6× |
| Interest cover | 1,272.2× | Good | 2.69× |
| Current ratio | 2.82× | Good | 2.39× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 9.9% | Good | 0% |
| Payout of free cash flow | 17.7% | Good | 28.8% |
| Payout of free cash flow (3 years) | 15.3% | Good | — |
| Dividend growth / year | 6.7% | Good | 7.1% |
| Years of rising dividends | 13 | Good | 2 |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow WST and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.